Monthly research recap
Neuroplasticity research: September 2026
What September 2026's 8 new studies found, synthesized from the papers below. All Neuroplasticity research →
The synthesis
Synthesized from 8 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Neuroplasticity, neural plasticity, brain plasticity, synaptic plasticity, neurogenesis, then ranked by relevance.
Research indexed in September 2026 on neuroplasticity is dominated by preclinical and theoretical work linking psychedelics and ketamine to plasticity-related mechanisms, with several studies reporting that these effects can occur independently of classical receptor activation or depend heavily on administration context. Empirical human evidence remains very thin: the only clinical study is a 7-person open-label pilot, and a systematic review concludes that clinical efficacy for chronic pain is not established. Overall the direction is promising but preliminary, with small samples, mixed preclinical results, and no durability data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Ketamine-enhanced psychotherapy for smoking cessation: A pilot study of feasibility, safety, and clinical outcomes. 2026 | open-label pilot study | 7 | Supports | Three weekly intramuscular ketamine sessions combined with motivational enhancement therapy were feasible and well tolerated, with decreased cigarette consumption and nicotine craving but stable withdrawal, dependence severity, and motivation to quit. |
| 5-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice. 2026 | controlled preclinical experiment in rodents | Supports | Psilocybin facilitated fear extinction and increased BDNF and doublecortin-positive neurons even when 5-HT2A receptors were blocked by ketanserin or MDL100907, indicating these effects do not require 5-HT2A activation. | |
| Botanical Context Biasing for Experience-Dependent Neuroplasticity: A Two-Timescale Hypothesis of Directional Reinforcement During Psilocybin-Induced Plasticity 2026 | theoretical | Unclear | Argues that companion botanicals co-formulated with psilocybin can bias the qualitative trajectory of the psychedelic state in reproducible, formulation-specific directions via a tonic layer over weeks and a phasic within-session layer, presented as a hypothesis from uncontrolled observations. | |
| Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network Organization 2026 | systematic review | Mixed | Preclinical results were mixed, including one rigorous null study finding no immediate or persistent analgesic effect, and human evidence was limited to one small open-label fibromyalgia pilot trial, case reports, case series, and surveys, judged insufficient to establish clinical efficacy. | |
| 515. Influence of the context of administration on 5-MeO-DMT-promoted antidepressant-like effects and neuroplasticity 2026 | preclinical experimental study | Mixed | 5-MeO-DMT at 0.5 mg/kg produced antidepressant-like effects in neutral or positive settings but not in a negative setting, which instead promoted anxiogenic-like responses; positive setting was associated with degradation of perineuronal nets around hippocampal parvalbumin interneurons. | |
| 753. The Mechanism of Ketamine’s Anti-Suicidal Action: From Glutamatergic Surge to Neuroplasticity via the Opioid-Attachment Interface 2026 | theoretical | Unclear | Proposes that ketamine's anti-suicidal effects rely on an acute glutamatergic-opioid interaction buffering anxiety from ego dissolution and social abandonment, targeting thwarted belongingness in insecure attachment phenotypes, followed by neuroplastic changes. | |
| 860. Glutamatergic Signaling and Neuroplasticity in Mood Disorders: A Historical Perspective from Preclinical Discoveries to Clinical Translation 2026 | narrative review | Supports | Argues that glutamatergic signaling links synaptic plasticity to mood disorder pathophysiology and treatment, with ketamine's rapid antidepressant effects involving NMDA receptor blockade, enhanced AMPA throughput, and mTORC1/eIF4E-dependent synaptogenesis, and serotonergic psychedelics sharing these plasticity mechanisms. | |
| The mPFC-reuniens-hippocampus pathway links brain circuitry and neural plasticity in antidepressant response 2026 | preclinical study | Supports | Chemogenetic activation of the infralimbic cortex produced rapid antidepressant-like effects mediated by the thalamic nucleus reuniens and ventral hippocampus, and inhibiting this IL-to-RE-to-vHIPP circuit blocked both IL-induced and ketamine-induced antidepressant and neuroplastic effects. |
Points of agreement
- Multiple preclinical and review studies link psychedelics and ketamine to neuroplasticity-related mechanisms such as BDNF upregulation, synaptogenesis, and structural plasticity.
- Plasticity-related effects of psilocybin and 5-MeO-DMT appear to depend on non-classical factors, including 5-HT2A-independent pathways and administration context.
- Several studies frame mood and pain disorders as disorders of neuroplasticity and propose circuit- or plasticity-level mechanisms for treatment response.
Conflicts
- Preclinical analgesic findings for psilocybin are mixed, with one rigorous null study contradicting positive rodent results.
- 5-MeO-DMT produced antidepressant-like effects in neutral or positive settings but anxiogenic-like responses in a negative setting, indicating context-dependent opposing outcomes.
- Psilocybin's fear extinction and plasticity effects were reported as 5-HT2A-independent, whereas some preclinical pain findings are linked to 5-HT2A signaling.
Gaps
- Human clinical evidence is limited to a single 7-participant open-label pilot and one small fibromyalgia trial, with no adequately powered randomized trials.
- Durability and long-term follow-up of plasticity-related effects are largely unaddressed.
- Blinding, active controls, and biomarkers are lacking in the clinical work.
- Most mechanistic evidence comes from male rodents, limiting generalizability across sexes and populations.
- Dose-response relationships and the role of administration context in humans remain poorly characterized.